Animal Model Data Presented at American Association for Cancer Research Indicate That Hemispherx Biopharma’s Ampligen(R) May be a Potent Tumor Vaccine Adjuvant

PHILADELPHIA, April 4, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced new data presented yesterday at the American Association for Cancer Research (“AACR”) 102nd Annual Meeting 2011 in Orlando (Abstract No. 748) by investigators from the Tumor Vaccine Group (“TVG”) at the University of Washington in Seattle, WA, which highlights the potential of Ampligen® to act as a potent tumor vaccine adjuvant.